Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 7/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29928966 | 0.86 | FASN (0.48) | PTGESALOX5FASNHIF1AEPAS1 | |
| SCHEMBL23044598 | 0.79 | PTGES (0.35) | PTGESALOX5FASNHIF1AEPAS1 | |
| SCHEMBL29929660 | 0.79 | PTGES (0.33) | PTGESALOX5FASNPTGS1 | |
| SCHEMBL29929432 | 0.79 | PTGES (0.33) | PTGESALOX5FASNPTGS1 | |
| SCHEMBL29377594 | 0.78 | FASN (0.46) | PTGESALOX5FASNPTGS1 | |
| SCHEMBL24075655 | 0.78 | MEN1 (0.49) | PTGESALOX5HIF1AEPAS1PTGS1 | |
| SCHEMBL23044596 | 0.77 | ALOX5 (0.35) | PTGESALOX5HIF1AEPAS1MEN1 | |
| SCHEMBL31580515 | 0.75 | MEN1 (0.49) | PTGESALOX5HIF1AEPAS1PTGS1 | |
| SCHEMBL3483228 | 0.73 | PTGES (0.41) | PTGESALOX5FASNHIF1AMEN1 | |
| SCHEMBL24074936 | 0.69 | PTGES (0.60) | PTGESALOX5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-7854946-B1 | Anti-inflammatory and anti-HIV compositions and methods of use | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2010-12-21 | — | — | US | claimed |
| WO-2010092162-A1 | NEUROACTIVE PLANT EXTRACT FROM HYPERICUM POLYANTHEMUM | UNIVERSITE DE ROUEN (FR) | 2010-08-19 | — | — | WO | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250161394-A1 | Compositions Comprising Kavalactones | NATURAL EXTRACTION SYS LLC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC | 2022-11-17 | — | — | US | disclosed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | disclosed |
| US-7854946-B1 | Anti-inflammatory and anti-HIV compositions and methods of use | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2010092162-A1 | NEUROACTIVE PLANT EXTRACT FROM HYPERICUM POLYANTHEMUM | UNIVERSITE DE ROUEN (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | PTGES 1679/4885ALOX5 264/4885FASN 1020/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | PTGES 1236/4885ALOX5 260/4885FASN 1957/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | PTGES 338/4885ALOX5 307/4885FASN 1507/4885 |
| US-20220362169-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | PRKG2, PRKG1, CIT | PTGES 1236/4885ALOX5 260/4885FASN 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.